We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and thoracic products (“CMF”); office based technologies; dental implants; and related surgical products. Our chief operating decision maker (“CODM”) allocates resources to achieve our operating profit goals through seven operating segments. Our operating segments are comprised of both geographic and product category business units. The geographic operating segments are the Americas, which is comprised principally of the U.S. and includes other North, Central and South American markets; EMEA, which is comprised principally of Europe and includes the Middle East and African markets; and Asia Pacific, which is comprised principally of Japan, China and Australia and includes other Asian and Pacific markets. The product category operating segments are Spine, Office Based Technologies, CMF and Dental. The geographic operating segments include results from all of our product categories except those in the product category operating segments. The Office Based Technologies, CMF and Dental product category operating segments reflect those respective product category results from all regions, whereas the Spine product category operating segment includes all spine product results excluding those from Asia Pacific.

As it relates to the geographic operating segments, our CODM evaluates performance based upon segment operating profit exclusive of operating expenses pertaining to inventory and manufacturing-related charges, intangible asset amortization, intangible asset impairment, acquisition, integration and related, quality remediation, litigation, litigation settlement gain, certain European Union Medical Device Regulation expenses, other charges, and global operations and corporate functions. Global operations and corporate functions include research, development engineering, medical education, brand management, corporate legal, finance and human resource functions, manufacturing operations and logistics and share-based payment expense. As it relates to each product category operating segment, research, development engineering, medical education, brand management and other various costs that are specific to the product category operating segment’s operations are reflected in its operating profit results. Due to these additional costs included in the product category operating segments, profitability metrics among the geographic operating segments and product category operating segments are not comparable. Intercompany transactions have been eliminated from segment operating profit.

Our CODM does not review asset information by operating segment. Instead, our CODM reviews cash flow and other financial ratios by operating segment.

These seven operating segments are the basis for our reportable segment information provided below. The four product category operating segments are individually insignificant to our consolidated results and therefore do not constitute a reporting

segment either individually or combined. For presentation purposes, these product category operating segments have been aggregated. Prior period reportable segment financial information has been restated to conform to the current presentation.

	Net Sales				Operating Profit
	Three Months Ended				Three Months Ended
	September 30,				September 30,
	2019		2018		2019			2018
Americas	$	961.2	$	934.5	$	517.3		$	493.7
EMEA		330.9		326.8		91.8			84.7
Asia Pacific		322.6		295.9		106.3			93.3
Product Category Operating Segments		277.7		279.5		39.1			42.7
Global Operations and Corporate Functions		-		-		(253.5	)		(243.4	)
Total	$	1,892.4	$	1,836.7
Inventory and manufacturing-related charges						(11.6	)		(5.0	)
Intangible asset amortization						(146.6	)		(147.6	)
Intangible asset impairment						-			(3.8	)
Acquisition, integration and related						0.9			(17.4	)
Quality remediation						(21.5	)		(34.2	)
Litigation						(42.8	)		(14.0	)
European Union Medical Device Regulation						(11.4	)		(0.8	)
Other charges						(22.2	)		(24.9	)
Operating profit					$	245.8		$	223.3

	Net Sales				Operating Profit
	Nine Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019			2018
Americas	$	2,925.7	$	2,904.9	$	1,563.2		$	1,556.0
EMEA		1,120.0		1,159.4		335.1			341.4
Asia Pacific		948.2		914.0		325.1			305.1
Product Category Operating Segments		862.6		883.6		129.7			135.3
Global Operations and Corporate Functions		-		-		(781.9	)		(733.5	)
Total	$	5,856.5	$	5,861.9
Inventory and manufacturing-related charges						(47.7	)		(24.7	)
Intangible asset amortization						(436.9	)		(447.9	)
Intangible asset impairment						(70.1	)		(3.8	)
Acquisition, integration and related						(20.3	)		(113.9	)
Quality remediation						(64.6	)		(125.8	)
Litigation						(48.0	)		(15.5	)
Litigation settlement gain						23.5			-
European Union Medical Device Regulation						(18.1	)		(1.6	)
Other charges						(88.3	)		(46.8	)
Operating profit					$	800.7		$	824.3